Noile-Immune Biotech

News Release

No. 25005
July 1, 2025
Noile-Immune Biotech Inc.
https://www.noile-immune.com/en.html

Notice of Subsidy Project Adoption for FY2025 Yamaguchi Advancements in Practical Application and Industrialization of Regenerative Medicine

Social Implementation of World's First Treatment for Solid Tumors by CAR-T Cell Therapy with Next-Generation Immune-Enhancing Technology and Formation of a Wide-Area Collaboration Base for Research and Development

Noile-Immune Biotech Inc. (hereinafter referred to as "Noile-Immune") hereby announces that "Social implementation of world's first treatment for solid tumors by CAR-T cell therapy with next-generation immune-enhancing technology and formation of a wide-area collaboration base for research and development" which Noile-Immune applied (hereinafter referred to as "Project") has been adopted as the subsidy project for "FY2025 Yamaguchi advancements in practical application and industrialization of regenerative medicine".

Noile-Immune is committed to the practical application of a truly effective treatment for solid tumors that still have limited therapeutic efficacy with conventional CAR-T cell therapy by utilizing next-generation PRIME CAR-T cells which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy.

The Project aims to conduct the development of next-generation manufacturing methods for the clinical development and commercial production of CAR-T cell therapy for solid tumors, using the Yamaguchi University-originated PRIME technology developed as a core, and to deliver truly effective therapies to patients suffering from cancer around the world. In addition, the Project also aims to build a foundation for the formation of a wide-area collaboration base for CAR-T cell therapy research and development of CAR-T cell therapy centering around Yamaguchi Prefecture.

<Outline of Subsidy Project>

- Project name: Social implementation of world's first treatment for solid tumors by CAR-T cell therapy with next-generation immune-enhancing technology and formation of a wide-area collaboration base for research and development
- Subsidized business operator: Noile-Immune Biotech Inc.
- Project period: 3 years at the most (up to FY2027)
- Maximum subsidy amount: 30 million yen/year

The potential impact in relation to this matter on the company's performance for the fiscal year ending December 31, 2025 is currently under careful review. However, should any matters arise that require disclosure, Noile-Immune will provide updates promptly.

【CAR-T cell therapy】

CAR-T cells are manufactured by introducing an artificial gene called a chimeric antigen receptor (CAR) into a type of white blood cell called T cells, which are taken from the patient's blood. The CAR has the ability to detect cancer cells with high sensitivity and to mount a strong attack against them. CAR-T cell therapy is a treatment in which CAR-T cells are expanded in culture for a certain period and then administered to the patient. CAR-T cells transfected with the CAR gene recognize and attack the cancer cells that express the target cancer antigen.



【Noile-Immune's proprietary PRIME technology (PRIME CAR-T cell therapy)】

PRIME technology is Noile-Immune's proprietary technology which further improves immune cells, such as CAR-T cells used for anti-cancer therapy, to produce interleukin-7 (IL-7) and CCL19, and has a potential to promote the growth and survival of T cells and to stimulate the migration of T cells and dendritic cells, so as to enhance the therapeutic effects against cancer. PRIME technology was developed to create an environment conducive to attacking cancer cells efficiently by inducing accumulation of a large number of CAR-T cells and body's immune cells at the site of cancer.

For more details, please visit https://www.noile-immune.com/en/Our_Science/prime_car-t.html.



【Noile-Immune Biotech Inc.】

Noile-Immune Biotech Inc. (TSE: 4893) is a biotech company, an academia start-up, and is committed to the practical application of next-generation immunotherapy for solid cancers by utilizing PRIME CAR-T cells which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance the therapeutic effects of immune cell therapy. As PRIME technology can be combined with various chimeric antigen receptors (CARs) to create novel drugs and applied to a broad range of modalities, it is expected to develop many anti-cancer therapeutic approaches in combination with other technologies in the future. Through our business activities, Noile-Immune aims to contribute to the creation of a society that can overcome cancer.

For more information, please visit https://www.noile-immune.com/en.html.